Published in:
01-05-2016 | Colorectal Cancer
Evaluating the Prognostic Role of Elevated Preoperative Carcinoembryonic Antigen Levels in Colon Cancer Patients: Results from the National Cancer Database
Authors:
Adan Z. Becerra, BA, Christian P. Probst, MD, Mohamedtaki A. Tejani, MD, Christopher T. Aquina, MD, Maynor G. González, PhD, Bradley J. Hensley, MD, MBA, Katia Noyes, PhD, John R. Monson, MD, Fergal J. Fleming, MD
Published in:
Annals of Surgical Oncology
|
Issue 5/2016
Login to get access
Abstract
Objectives
Carcinoembryonic antigen (CEA) is a reliable tumor marker for the management and surveillance of colon cancer. However, limitations in previous studies have made it difficult to elucidate whether CEA should be established as a prognostic indicator. This study examines the association between elevated preoperative CEA levels and overall survival in colon cancer patients using a national population-based registry.
Methods
Stage I–III colon cancer patients were identified from the 2004–2006 National Cancer Database. A multivariable Cox proportional hazards model was used to estimate the association between elevated CEA levels and overall survival after controlling for important patient, hospital, and tumor characteristics. A Monte Carlo Markov Chain was used to impute the large degree of missing CEA data. All models controlled for the propensity score in order to account for selection bias.
Results
A total of 137,381 patients met the inclusion criteria. Overall, 34 % of patients had an elevated CEA level and 66 % had a normal CEA level, with a median survival of 70 and 100 months, respectively. Patients with an elevated CEA level had a 62 % increase in the hazard of death (HR 1.62, 95 % CI 1.53–1.74) compared with patients with a normal CEA level.
Conclusions
Preoperative CEA was an independent predictor of overall survival across all stages. The results support recommendations to include CEA levels as another high-risk feature that clinicians can use to counsel patients on adjuvant chemotherapy, especially for stage II patients.